Clinical trials: SGLT 2 Inhibitors, open to volunteers
Solid Tumor, SGLT 2 Inhibitors
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Revised version: Locally advanced or advanced solid tumors remain a major clinical challenge despite multimodal treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
- Trial name
- SGLT2SOLID (NCT07703163)
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
CAD - Coronary Artery Disease, Inflamation
Effect of Empagliflozin on Inflammation
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure.
- Conditions
- CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
- Trial name
- EMPANTINFLAM (NCT07292909)
- Testing
- Empagliflozin (SGLT2i)
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Hotel Dieu de France Hospital
SGLT 2 Inhibitors
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after…
- Trial name
- NCT07186153
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University
Colorectal Cancer, SGLT-2 Inhibitor
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
Colorectal cancer (CRC), ranking third in incidence among men and second in women globally with third-highest mortality in the US, remains a major health challenge despite multimodal therapies, particularly for advanced-stage…
- Trial name
- NCT07076823
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
SGLT-2 Inhibitor, Atrial Fibrillation
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus.
- Conditions
- SGLT-2 Inhibitor, Atrial Fibrillation, Diabetes Mellitus, Type 2
- Trial name
- NCT05029115
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 716 people
- Sponsor
- Ewha Womans University Mokdong Hospital